Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion

European Journal of Haematology

Volumn 96, Issue 3, 2016, Pages 229-235

  Tempescul, Adrian ^a,b   Bagacean, Cristina ^b   Riou, Catherine ^a,b   Bendaoud, Boutahar ^a,b   Hillion, Sophie ^a,b   Debant, Marjolaine ^b   Buors, Caroline ^c   Berthou, Christian ^a,b   Renaudineau, Yves ^a,b  

^a CHU MORVAN   (France)

^b INSERM   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Chronic lymphocytic leukaemia; Complement; Fc RIII polymorphism; Ofatumumab

Indexed keywords

CD19 ANTIGEN; CD5 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FC RECEPTOR IIA; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; VERY ELDERLY; ADOLESCENT; CHILD; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; COMPLEMENT C3; COMPLEMENT C4; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, IGG; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958109879     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12573     Document Type: Article

References (25)

1. Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 2013;88:803-16.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
4. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014;124:49-62.
5. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-100.
6. Du J, Yang H, Guo Y, et al. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009;46:2419-23.
7. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011;118:5126-9.
8. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749-58.
9. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012;156:490-8.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Blood 2011;117:5019-32.
11. Cornec D, Tempescul A, Querellou S, et al. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Ann Hematol 2012;91:715-21.
12. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56.
13. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98:29-35.
14. Middleton O, Cosimo E, Dobbin E, et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 2015;29:107-14.
15. Fust G, Czink E, Minh D, et al. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol 1985;60:489-95.
16. Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188:3532-41.
17. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800.
18. Xu W, Miao KR, Zhu DX, et al. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer 2011;128:2192-201.
19. Sebejova L, Borsky M, Jaskova Z, et al. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Exp Hematol 2014;42:867-74. e861.
20. Bologna L, Gotti E, Da Roit F, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013;190:231-9.
21. Mishima Y, Terui Y, Kuniyoshi R, et al. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism. Int Immunol 2012;24:477-83.
22. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
23. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
24. Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010;116:4212-22.
25. Moga E, Canto E, Vidal S, et al. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Exp Hematol 2011;39:1064-71.